SAO PAULO (Reuters) – The government of Brazil’s Sao Paulo state signed a $90 million contract on Wednesday to receive 46 million doses of a potential vaccine from China’s Sinovac Biotech Ltd.
Sao Paulo, Brazil’s most populous state, is one of the sites of Phase III clinical trials for the Sinovac vaccine conducted by the state’s Butantan Institute, a leading biomedical research center.
By Eduardo Simões via Swissinfo.ch